Clearside BiomedicalCLSD
Market Cap: $72.5M
About: Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
Employees: 30
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
2.56% less ownership
Funds ownership: 20.98% [Q1] → 18.42% (-2.56%) [Q2]
6% less funds holding
Funds holding: 52 [Q1] → 49 (-3) [Q2]
25% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 16
25% less capital invested
Capital invested by funds: $24M [Q1] → $17.9M (-$6.09M) [Q2]
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
HC Wainwright & Co. Yi Chen 32% 1-year accuracy 44 / 139 met price target | 415%upside $5 | Buy Reiterated | 27 Aug 2024 |
Chardan Capital Daniil Gataulin 18% 1-year accuracy 3 / 17 met price target | 519%upside $6 | Buy Initiated | 21 Aug 2024 |
HC Wainwright & Co. Yi Chen 32% 1-year accuracy 44 / 139 met price target | 415%upside $5 | Buy Reiterated | 13 Aug 2024 |
Needham Serge Belanger 41% 1-year accuracy 47 / 114 met price target | 312%upside $4 | Buy Reiterated | 13 Aug 2024 |
HC Wainwright & Co. Yi Chen 32% 1-year accuracy 44 / 139 met price target | 415%upside $5 | Buy Reiterated | 30 Jul 2024 |
Financial journalist opinion
Based on 3 articles about CLSD published over the past 30 days